nach oben

Pathology & Oncology Research

Erschienen in:

20.11.2019 | Original Article

Identification of GIMAP7 and Rabl3 as Putative Biomarkers for Oral Squamous Cell Carcinoma Through Comparative Proteomic Approach

verfasst von: Muhammad Usman, Amber Ilyas, Zehra Hashim, Shamshad Zarina

Erschienen in: Pathology & Oncology Research | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Oral squamous cell carcinoma (OSCC) accounts for more than 90% of all oral cancers and has been listed as sixth most common human cancer. Due to late diagnosis and insufficient therapeutic response among patients, the survival rate remains very low accentuating the importance of early diagnostic markers. The study aimed to identify differentially expressed proteins in search for putative serum biomarkers and drug targets. Serum samples (n = 45) were depleted and resolved on two dimensional gel electrophoresis. Among differentially expressed proteins, two were identified using MALDI-TOF mass spectrometry. Gene expression levels of identified proteins were quantified in malignant and normal tissue using RT-qPCR. To validate serum Rabl3 expression, sandwich ELISA was performed. Proteomics analysis revealed two proteins which were found to be associated with oral cancer. The expression of GIMAP7 was found to be down regulated in serum of patients suffering from oral cancer while the expression of Rabl3 was found to be up-regulated. Gene expression analysis in malignant tissue and adjacent normal tissue revealed the same pattern. Quantitative ELISA was used to validate expression of Rabl3 in serum from oral cancer patients and healthy subjects which demonstrated significant up-regulation in cancer patients. Findings in current study demonstrate differential expression of novel putative biomarkers GIMAP7 and Rabl3 in oral cancer which suggests their potential role in oral cancer pathology and can be considered as predictive biomarkers.

Leemans CR, Braakhuis BJ, Brakenhoff RH (2011) The molecular biology of head and neck cancer. Nat Rev Cancer 11(1):9–22. https://doi.org/10.1038/nrc2982 CrossRefPubMed

Arantes LMRB, de Carvalho AC, Melendez ME, Carvalho AL, Goloni-Bertollo EM (2014) Methylation as a biomarker for head and neck cancer. Oral Oncol 50(6):587–592. https://doi.org/10.1016/j.oraloncology.2014.02.015 CrossRefPubMed

Tanaka T, Tanaka M, Tanaka T (2011) Oral carcinogenesis and oral cancer chemoprevention: a review. Pathol Res Int 2011:431246–431246. https://doi.org/10.4061/2011/431246 CrossRef

Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 68(6):394–424. https://doi.org/10.3322/caac.21492 CrossRefPubMed

Ali NS, Khuwaja AK, Ali T, Hameed R (2009) Smokeless tobacco use among adult patients who visited family practice clinics in Karachi, Pakistan. J Oral Pathol Med 38(5):416–421CrossRefPubMed

Johnson N (2001) Tobacco use and oral cancer: a global perspective. J Dent Educ 65(4):328–339CrossRefPubMed

Khan Z, Tönnies J, Müller S (2014) Smokeless tobacco and oral cancer in South Asia: a systematic review with meta-analysis. J Cancer Epidemiol 2014:394696–394696. https://doi.org/10.1155/2014/3946960 CrossRefPubMedPubMedCentral

Gigliotti J, Madathil S, Makhoul N (2019) Delays in oral cavity cancer. Int J Oral Maxillofac Surg. https://doi.org/10.1016/j.ijom.2019.02.015

Barbosa EB, Vidotto A, Polachini GM, Henrique T, Marqui AB, Tajara EH (2012) Proteomics: methodologies and applications to the study of human diseases. Rev Assoc Med Bras 58(3):366–375PubMed

10.

Turhani D, Krapfenbauer K, Thurnher D, Langen H, Fountoulakis M (2006) Identification of differentially expressed, tumor-associated proteins in oral squamous cell carcinoma by proteomic analysis. Electrophoresis 27(7):1417–1423. https://doi.org/10.1002/elps.200500510 CrossRefPubMed

11.

Malik UU, Zarina S, Pennington SR (2016) Oral squamous cell carcinoma: key clinical questions, biomarker discovery, and the role of proteomics. Arch Oral Biol 63:53–65. https://doi.org/10.1016/j.archoralbio.2015.11.017 CrossRefPubMed

12.

Blatt S, Kruger M, Ziebart T, Sagheb K, Schiegnitz E, Goetze E, Al-Nawas B, Pabst AM (2017) Biomarkers in diagnosis and therapy of oral squamous cell carcinoma: a review of the literature. J Craniomaxillofac Surg 45(5):722–730. https://doi.org/10.1016/j.jcms.2017.01.033 CrossRefPubMed

13.

Beretta L (2007) Proteomics from the clinical perspective: many hopes and much debate. Nat Methods 4(10):785–786. https://doi.org/10.1038/nmeth1007-785 CrossRefPubMed

14.

Fernández-Olavarría A, Mosquera-Pérez R, Díaz-Sánchez R-M, Serrera-Figallo M-A, Gutiérrez-Pérez J-L, Torres-Lagares D (2016) The role of serum biomarkers in the diagnosis and prognosis of oral cancer: a systematic review. J Clin Exp Dent 8(2):e184–e193. https://doi.org/10.4317/jced.52736 CrossRefPubMedPubMedCentral

15.

Ilyas A, Hashim Z, Zarina S (2015) Effects of 5'-azacytidine and alendronate on a hepatocellular carcinoma cell line: a proteomics perspective. Mol Cell Biochem 405(1-2):53–61. https://doi.org/10.1007/s11010-015-2395-1 CrossRefPubMed

16.

Musharraf SG, Hashmi N, Choudhary MI, Rizvi N, Usman A, Atta ur R (2012) Comparison of plasma from healthy nonsmokers, smokers, and lung cancer patients: pattern-based differentiation profiling of low molecular weight proteins and peptides by magnetic bead technology with MALDI-TOF MS. Biomarkers 17(3):223–230. https://doi.org/10.3109/1354750x.2012.657245 CrossRefPubMed

17.

Bhurgri Y (2005) Cancer of the oral cavity - trends in Karachi South (1995-2002). Asian Pac J Cancer Prev 6(1):22–26PubMed

18.

Chen Y, Azman SN, Kerishnan JP, Zain RB, Chen YN, Wong YL, Gopinath SC (2014) Identification of host-immune response protein candidates in the sera of human oral squamous cell carcinoma patients. PLoS One 9(10):e109012. https://doi.org/10.1371/journal.pone.0109012 CrossRefPubMedPubMedCentral

19.

Nitta T, Nasreen M, Seike T, Goji A, Ohigashi I, Miyazaki T, Ohta T, Kanno M, Takahama Y (2006) IAN family critically regulates survival and development of T lymphocytes. PLoS Biol 4(4):e103. https://doi.org/10.1371/journal.pbio.0040103 CrossRefPubMedPubMedCentral

20.

Poirier GM, Anderson G, Huvar A, Wagaman PC, Shuttleworth J, Jenkinson E, Jackson MR, Peterson PA, Erlander MG (1999) Immune-associated nucleotide-1 (IAN-1) is a thymic selection marker and defines a novel gene family conserved in plants. J Immunol 163(9):4960–4969PubMed

21.

Pandarpurkar M, Wilson-Fritch L, Corvera S, Markholst H, Hornum L, Greiner DL, Mordes JP, Rossini AA, Bortell R (2003) Ian4 is required for mitochondrial integrity and T cell survival. Proc Natl Acad Sci U S A 100(18):10382–10387. https://doi.org/10.1073/pnas.1832170100 CrossRefPubMedPubMedCentral

22.

Schnell S, Demolliere C, van den Berk P, Jacobs H (2006) Gimap4 accelerates T-cell death. Blood 108(2):591–599. https://doi.org/10.1182/blood-2005-11-4616 CrossRefPubMed

23.

Shiao YM, Chang YH, Liu YM, Li JC, Su JS, Liu KJ, Liu YF, Lin MW, Tsai SF (2008) Dysregulation of GIMAP genes in non-small cell lung cancer. Lung Cancer 62(3):287–294. https://doi.org/10.1016/j.lungcan.2008.03.021 CrossRefPubMed

24.

Huang Z, Zhang W, Gao C, Ji B, Chi X, Zheng W, Wang HL (2016) Dysregulation of GTPase IMAP family members in hepatocellular cancer. Mol Med Rep 14(5):4119–4123. https://doi.org/10.3892/mmr.2016.5764 CrossRefPubMedPubMedCentral

25.

Colicelli J (2004) Human RAS superfamily proteins and related GTPases. Sci STKE 2004(250):Re13. https://doi.org/10.1126/stke.2502004re13 CrossRefPubMedPubMedCentral

26.

Agarwal R, Jurisica I, Mills GB, Cheng KW (2009) The emerging role of the RAB25 small GTPase in cancer. Traffic (Copenhagen, Denmark) 10(11):1561–1568. https://doi.org/10.1111/j.1600-0854.2009.00969.x CrossRef

27.

Li Q, Wang L, Zeng L, Zhang Y, Li K, Jin P, Su B, Wang L (2010) Evaluation of the novel gene Rabl3 in the regulation of proliferation and motility in human cancer cells. Oncol Rep 24(2):433–440PubMed

28.

Zhang W, Sun J, Luo J (2016) High expression of Rab-like 3 (Rabl3) is associated with poor survival of patients with non-small cell lung cancer via repression of MAPK8/9/10-Mediated autophagy. Med Sci Monit 22:1582–1588. https://doi.org/10.12659/MSM.898632 CrossRefPubMedPubMedCentral

29.

Pan Y, Liu Z, Feng Z, Hui D, Huang X, Tong D, Jin Y (2017) The overexpression of Rabl3 is associated with pathogenesis and clinicopathologic variables in hepatocellular carcinoma. Tumour Biol 39(4):1010428317696230. https://doi.org/10.1177/1010428317696230 CrossRefPubMed

30.

An J, Liu Z, Liang Q, Pan Y, Li H, Wang R, Jin Y (2017) Overexpression of Rabl3 and Cullin7 is associated with pathogenesis and poor prognosis in hepatocellular carcinoma. Hum Pathol 67:146–151. https://doi.org/10.1016/j.humpath.2017.07.008 CrossRefPubMed

Titel: Identification of GIMAP7 and Rabl3 as Putative Biomarkers for Oral Squamous Cell Carcinoma Through Comparative Proteomic Approach
verfasst von: Muhammad Usman
Amber Ilyas
Zehra Hashim
Shamshad Zarina
Publikationsdatum: 20.11.2019
Verlag: Springer Netherlands
Erschienen in: Pathology & Oncology Research / Ausgabe 3/2020
Print ISSN: 1219-4956
Elektronische ISSN: 1532-2807
DOI: https://doi.org/10.1007/s12253-019-00775-1

Neu im Fachgebiet Onkologie

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gut molekulare Response, aber seltener ernste Nebenwirkungen.

Brustkrebs-Prävention wird neu gedacht

04.06.2024 ASCO 2024 Kongressbericht

Zurzeit untersuchen Forschende verschiedene neue Ansätze zur Prävention von Brustkrebs bei Personen mit hohem Risiko. Darunter Denosumab, die prophylaktische Bestrahlung der Brust – und Impfungen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 3/2020

Tight Junction-Related CLDN5 and CLDN6 Genes, and Gap Junction-Related GJB6 and GJB7 Genes Are Somatically Mutated in Gastric and Colorectal Cancers

Association of Plasma Epstein-Barr Virus LMP1 and EBER1 with Circulating Tumor Cells and the Metastasis of Nasopharyngeal Carcinoma

Hsa_circ_0065149 is an Indicator for Early Gastric Cancer Screening and Prognosis Prediction

Prognostic and Clinicopathological Correlations of Cell Cycle Marker Expressions before and after the Primary Systemic Therapy of Breast Cancer

Bioinformatics Analysis Suggests the Combined Expression of AURKB and KIF18B Being an Important Event in the Development of Clear Cell Renal Cell Carcinoma